Drug Manufacturers

Transparency on drug trials

Financial Times (Free subscription) | yesterday

The pharmaceutical industry will next May begin publishing details of early stage drug tests in patients, to boost transparency in research. The move was unveiled by...

Doctor had lucrative ties to drug firm

Chicago Breaking News (Free subscription) | 6 hours ago

Executives inside pharmaceutical giant AstraZeneca faced a high-stakes dilemma. On one hand, Chicago psychiatrist Dr. Michael Reinstein was bringing the company a small fortune in sales and was conducting research that made one of its most promising drugs look spectacular. On the other, some worried that his research findings might be too good to be true. As Reinstein grew irritated with what he perceived...

FDA extends review of XenoPort-Glaxo pain drug

Seattle Times (Free subscription) | 11/09/2009

The Food and Drug Administration needs three more months to review an application to a neuropathic pain drug being developed by XenoPort Inc. and GlaxoSmithKline PLC, the companies said.

• FDA extends review of XenoPort-Glaxo pain drug - Daily Advance - Business
• FDA extends review of XenoPort-Glaxo pain drug - San Fransisco Chronicle
• See the 4 articles on the same subject

Drug firm to cut nearly 100 jobs

BBC News (Free subscription) | yesterday

Drug maker Pfizer is closing its research and development sites in Berkshire and Hampshire next year.

Emergency pills to maintain OTC drug status

Indian Express (Free subscription) | 11/10/2009

In what comes as a relief to the largest domestic drug firm Cipla and Delhi-based Mankind Pharma which were accused for going overboard with promotion of 'morning after pills', the emergency contraceptive pill would remain an over the counter drug in India.

What's Up, Better Late Than Never, Edition

A Spork in the Drawer (Free subscription) | yesterday

posted by gyma Some days are better than others.... Happy Birthday to computer viruses, those good for nothing annoyances that make my life miserable. Thumbs down! Maybe Americans aren't as dumb as they appear - the majority blame drug manufacturers...

Nutt row deepens as more scientists quit

Mark Easton's UK (Free subscription) | yesterday

What does the phrase "the discussions were very constructive" mean? Apparently, inside the Home Office it means a meeting between the home secretary and his drug advisors that ends with three more eminent scientists announcing their resignations. Alan Johnson has got himself into a difficult place over his decision to sack the head of the Advisory Council on the Misuse of Drugs (ACMD). He...

Notable ETF Movers: PGM, XLV, SMH Up; UNG, KRE, FXI, AGQ, XME Down

StreetInsider.com News Articles (Free subscription) | yesterday

StreetInsider.com Notable ETF Movers: HIGHER: iPath DJ AIG Platinum TR Sub-Idx ETN (NYSE: PGM) Up 6.10%, as platinum futures are down about 1.4%. Investors might be looking for exposure in a different metals other than gold and silver, as many commodities have been having a good year so far. Health Care Select Sector SPDR (NYSE: XLV) up about 0.50%. Major holdings include Johnson & Johnson (NYSE:...

SMI Invests $10 Million in HealthSport

Contract Pharma Breaking News (Free subscription) | yesterday

SMI Manufacturing (Booth 1709) has agreed to invest $10 million into HealthSport, Inc., a formulator and developer of edible, multi-layer film strips that deliver drug and dietary supplement actives through buccal and sublingual absorption as well as oral ingestion. The investment is expected to accelerate HealthSport's growth and strengthen its alliances with large pharmaceutical companies. "The...

Executive Appointments at Patheon

Contract Pharma Breaking News (Free subscription) | yesterday

Patheon (Booth 1232) has named William E. Weiser, Ph.D. to the role of group director, Pharmaceutical Development Services (PDS), Analytical Development at the company's Kit Creek laboratory in Research Triangle Park, NC. Also, Anthony Qu, Ph.D. has been named group director of the PDS operation in Cincinnati, OH. "We are so pleased that we have been able to add these two individuals to our organization,"...

Pfizer outlines deep cuts in R&D shakeup

Fiercebiotech (Free subscription) | yesterday

New details on the impact of Pfizer's big R&D shakeup are coming in from around the world this morning. There's still no word on exactly how many of the 14,500 people working in research for Wyeth and Pfizer will be laid off. But the company said those cuts would make up a "considerable" segment of the 15 percent job cuts being planned across the board. Overall, Pfizer is shuttering...

Pfizer to close facilities, cut up to 2,000 jobs

The Washington Times (Free subscription) | yesterday

TRENTON, N.J. | Less than a month after buying Wyeth, drug giant Pfizer Inc. has mapped out a new structure for its research and development operations. The plan, announced Monday, will close six of the two companies' 20 research facilities, reorganize and consolidate others, and cut the jobs of up to 2,000 scientists and laboratory technicians. Pfizer, which is based in New York, solidified its position...

• Pfizer trimming research plants after buying Wyeth - Salt Lake Tribune
• Pfizer says cuts will spare La Jolla labs - San Diego Union
• See the 15 articles on the same subject

GSK reveals gift of 50m swine flu jabs to WHO

France24 (Free subscription) | yesterday

British pharmaceutical giant GlaxoSmithKline (GSK) said on Tuesday it will donate 50 million doses of its swine flu vaccine to the World Health Organisation (WHO) to distribute to developing countries. The drugs company is working with the WHO and health authorities to deliver initial shipments of the H1N1 vaccine by the end of November, it said in a statement. "GSK is committed to supporting...

Status of Pfizer and Wyeth research facilities

Miami Herald (Free subscription) | 11/10/2009

Pfizer Inc., which just acquired fellow drugmaker Wyeth, is closing six of the two companies' research sites and keeping open 14 others. Two Cambridge, Mass., sites will operate as one. Following is a list of the sites:

• Status of Pfizer and Wyeth research facilities - Daily Advance - Business
• Status of Pfizer and Wyeth research facilities - Seattle Post-Intelligencer

Zacks Bull and Bear of the Day Highlights: Inspire Pharmaceuticals, Inc., Sears Holdings, Moody's Corp., CBS Corporation and Forest Oil Corporation

Business Wire (Free subscription) | 11/09/2009

CHICAGO--(BUSINESS WIRE)--Zacks Equity Research highlights Inspire Pharmaceuticals, Inc. (Nasdaq: ISPH) as the Bull of the Day and Sears Holdings (Nasdaq: SHLD) the Bear of the Day. In addition, Zacks Equity Research provides analysis on Moody's Corp. (NYSE: MCO), CBS Corporation (NYSE: CBS) and Forest Oil Corporation (NYSE: FST). Full analysis of all these stocks is available at http://at.zacks.com/?id=2678....

ERP Products in india

eresource infotech | 11/09/2009

ERP Products in india One stop for all your ERP software solution ERESOURCEERP Products An effective solution for Pharmaceutical Industry For any Pharmaceutical ERP, compliance with GMP & FDA requirement considered as prime importance. Though 21 CFR Part II has been launched, many companies yet to tackle its practical implementation. User-friendly Eresource ERP is compliant to all statutory regulation...

Middle East and Africa pharmaceutical market poised to grow 11% annually till 2012

bharatbook | 10/30/2009

The Middle East and Africa pharmaceutical industry is entering a new era, with the development of infrastructure system and rapidly changing regulations. The industry is blessed with several advantages like high prevalence of diseases, huge population base and many more, reflecting bight prospects of growth in coming years. With these supportive factors, the pharmaceutical industry in the MEA region

Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery

aarkstore | 10/23/2009

Summary Global Drug Manufacturing Industry Outlook to 2010: Marketing & Sales Strategies and the Impact of Recession and Recovery” is a new report published by in association with ICD Research that analyzes how drugs manufacturer's and equipment, materials and service supplier's media spend, marketing and sales strategies & practices and business are being affected by the recession. In an uncertain...